NCT06189170

Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients

A Phase I, Randomised, Double-Blinded, Placebo-Controlled Study to Evaluate KP405. Part 1: Single Ascending Dosing in Healthy Participants. Part 2: Multiple Ascending Dosing in Healthy Participants and Parkinson's Disease Patients.

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 88 (estimated)
• Sponsor: Kariya Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of KP405 as a potential new treatment for Parkinson's disease.

Conditions

• Safety Issues
• Tolerance

Interventions

Type	Name	Description
DRUG	KP405	Experimental drug
DRUG	Placebo	Placebo

Timeline

• Start date: 2024-08-01
• Primary completion: 2025-12-31
• Completion: 2026-03-31
• First posted: 2024-01-03
• Last updated: 2025-03-07

Locations

1 site across 1 country: United Kingdom